Serum indoxyl sulfate (IS; a uremic toxin) levels, which are significantly higher in patients with chronic kidney disease, including those undergoing hemodialysis, than in the robust, are associated with both cardiovascular disease (CVD) and CVD-related mortality. Furthermore, coronary artery calcium (CAC) is an independent predictor of cardiovascular events in patients undergoing hemodialysis. This study aimed to interpret the association between serum IS levels and coronary plaque burden (CPB) or CAC.
C ardiovascular disease (CVD) is the main cause of death in patients undergoing maintenance dialysis. 1, 2) Mortality due to CVD is 10-30 times higher in patients undergoing hemodialysis than in the general population.
3) Moreover, it is well known that patients undergoing hemodialysis develop more severe coronary artery calcium (CAC) than healthy subjects and CVD patients without chronic kidney disease (CKD). 4, 5) Several studies suggest that CAC is an independent risk factor of cardiovascular events. 6, 7) Therefore, it may be important to prevent CAC in patients undergoing hemodialysis. Despite this, the current understanding of CAC in patients undergoing hemodialysis is insufficient to advance any promising therapeutic strategies.
Indoxyl sulfate (IS), a uremic toxin associated with the progression of CKD, 8) was recently shown to activate inflammatory markers and promote atherosclerosis. 9) Incidentally, serum IS levels are associated with both CVD and CVD-related mortality. 10) However, the underlying mechanism of this association remains unclear. On a different note, a study using integrated backscatter intravascular ultrasound (IB-IVUS) found that serum IS levels are positively correlated with lipid-rich coronary plaque, 11) as well as with advanced glycation end products, which are considered independent CAC predictors. 12) Furthermore, serum IS levels are higher in patients undergoing hemodialysis than in those with CKD who are not undergoing hemodialysis because standard hemodialysis eliminates IS only slightly or not at all.
10) The present study investigated the impact of serum IS accumulation on coronary plaque burden (CPB) and CAC, which were measured using 320-row multidetector computed tomography (MDCT), in patients undergoing hemodialysis.
Methods
Patient population: This prospective observational study was conducted with 30 consecutive adult patients on hemodialysis who underwent coronary CT angiography using 320-row MDCT (Aquilion ONE; Toshiba Medical Systems, Nasu, Japan) for suspected coronary artery disease (CAD) at our institution between December 2012 and November 2013. The CAD symptoms considered were angina, unstable blood pressure during hemodialysis, and abnormal electrocardiographic or echocardiographic findings at rest or during effort. The exclusion parameters were prior coronary revascularization (coronary artery stenting or coronary artery bypass grafting), prior pacemaker implantation, and severe heart failure (New York Heart Association Classification III or IV).
This study was conducted in accordance with the Declaration of Helsinki. All subjects signed a written informed consent. The institutional ethics committee approved the study protocol, which was registered in the university hospital medical information network (UMIN; clinical trial registration: UMIN000009500). Study design: All subjects first underwent a medical examination and interview to assess their coronary risk factors (available in the online data supplement). On a dialysis-free day, blood samples were collected from all subjects; serum IS levels and various oxidative and inflammatory markers [8-hydroxy-2'-deoxyguanosine, asymmetric dimethylarginine (ADMA), pentraxin 3, transforming growth factor-β, E-selectin, and intercellular adhesion molecule-1] were measured at an independent institution. On the same morning, all subjects underwent 320-row MDCT. Within 1 month before or after MDCT, all subjects underwent echocardiography and carotid artery ultrasound. The left ventricular ejection fraction (LVEF) and the intima-media thickness of the right and left carotid arteries (CA-IMT) were measured. Patients were followed up for 1 year after MDCT through in-hospital visits or telephone interviews. Computed tomography: Three hours before 320-row MDCT, all subjects exhibiting a heart rate (HR) > 65 beats per minute received 20 mg of metoprolol orally (Novartis Pharma K.K., Tokyo, Japan). 13) If the HR remained > 60 beats per minute before the scan, 0.125 mg/ kg of an ultra-short-acting β-blocker (landiolol; Ono Pharmaceutical Co., LTD., Osaka, Japan) was administered intravenously to further reduce the HR. 14) Immediately before image acquisition, almost all patients received 0.3 mg of nitroglycerin sublingually. The scan parameters were as follows: a collimation of 320 rows × 0.5 mm, a rotation time of 350-400 ms, and a tube voltage of 120 kV. The tube current (270-400 mA) was selected on the basis of the standard deviation of the noise level, which was measured using the CT scan projection radiograph. Electrocardiogram-gated, non-enhanced scans were obtained; subsequently, 370 mg/mL of iopamiron (Iopamiron; Bayer Schering Pharma, Osaka, Japan) was injected at a rate of 4.0-5.0 mL/s for 10 s, and contrast-enhanced scans were then acquired. Phase-NAVI scanner software (Toshiba Medical Systems, Nasu, Japan) automatically determined the appropriate cardiac phase (i.e., the phase with minimal cardiac motion) for MDCT axial image reconstruction. All data were acquired using 0.5-mm-thick slices and reconstructed using a standard kernel of FC04.
QAngio CT software (ver. 1.3.8; Medis Medical Imaging Systems, Leiden, The Netherlands) was used for the quantitative CT analysis, 15) and the MDCT data were analyzed by experienced observers who were blinded to the clinical data. Morphometric analysis of the coronary vessels: All coronary vessels with a diameter ! 1.5 mm were included in the analysis. The contour and lumen were traced using semi-automated algorithms. The coronary plaque volume was calculated as the sum of all voxels located between the vessel wall and the lumen contour. The calcification volume was calculated as the sum of all voxels of > 130 Hounsfield units that were located within the coronary plaque, as determined using the non-enhanced scans and following the Agatston approach.
16) The percent atheroma volume (PAV) and percent calcium volume (PCV) were calculated using the following equations: PAV = (total vessel wall volume -total lumen volume)/total vessel wall volume × 100% PCV = total calcium volume/total vessel wall volume × 100%
For the volumetric analysis, the entire coronary artery tree was divided into four vessels: the left main coronary artery (LMCA), left anterior descending artery (LAD), left circumflex artery (LCx), and right coronary artery (RCA). The LMCA extended from the aorta ostia to the bifurcation between LAD and LCx.
Within the coronary vessels, lesions were identified using an algorithm that measures both the minimum lumen area (MLA) and minimum lumen diameter (MLD). The percent lumen area stenosis was calculated as MLA divided by the mean proximal and distal reference lumen area. The percent lumen diameter stenosis (%DS) was calculated as MLD divided by the mean proximal and distal reference lumen diameters. The proximal and distal reference values were defined in healthy segments adjacent to the lesions. A %DS value of > 50% was considered significant. The remodeling index was defined as the outer vessel area at the site of maximum luminal narrowing divided by the mean areas of the proximal and distal reference sites.
17)
Statistical analysis: Continuous variables are expressed as mean ± standard deviation, and categorical variables are expressed as numbers and percentages. Linear mixed models were constructed in which continuous endpoints (i.e., PAV and PCV) were included as linear response variables. All clinically relevant explanatory variables were included in the univariate and/or the multivariable full model (Supplemental Table I ). Among these, the independent predictors were identified using the minimum Akaike's information criterion (AIC), following the backward stepwise approach. The LAD, LCx, RCA, and LMCA measurements were included as a random intercept in all models. Composite cardiovascular events within the 1 year follow-up were evaluated using the KaplanMeier method. The hazard ratio and confidence interval (CI) were calculated for each factor using Cox proportional hazards regression. All statistical analyses were per-ASSOCIATION BETWEEN IS AND CORONARY PLAQUES Without insulin, n (%) 9 (30.0)
12 ( Values are mean ± standard deviation where appropriate. ACE-I/ ARB indicates angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; CAD, coronary artery disease; CA-IMT, carotid artery intima-media thickness; CCS scale, Canadian Cardiovascular Society Angina scale; HD, hemodialysis; hs-CRP, high-sensitivity C-reactive protein; and LVEF, left ventricular ejection fraction. Values are mean ± standard deviation where appropriate. 8-OHdG indicates 8-hydroxy-2 -deoxyguanosine; ADMA, asymmetric dimethylarginine; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; ICAM-1, intercellular adhesion molecule-1; LDL, low-density lipoprotein; and TGF-β, transforming growth factor-β.
formed using R software version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria), and P values of < 0.05 were considered statistically significant.
Results

Clinical characteristics:
The baseline characteristics of the 30 subjects enrolled in this study are presented in Table I. The mean age was 67. Functional assessment of cardiac function indicated that the mean LVEF was 60.0% ± 13.0%, which is within the normal range. Blood analysis indicated that serum IS levels were elevated, with a mean value of 3.05 ± 1.43 mg/ dL (Table II) . Morphometric analysis of the coronary vessels: Complete volumetric analysis of the four coronary vessels was performed in all 30 subjects (120 vessels; Table III) . A total of 15 subjects (50.0%) showed significant stenosis in at least one vessel. Severe stenosis was generally located in LAD and RCA, whereas the remodeling index was comparable among all four vessels. The mean PAV and PCV values were 57.7% ± 7.95% and 16.3% ± 19.2%, respectively. Univariate and multivariable analyses: Univariate analyses indicated that PAV was positively associated with the female sex, right and left CA-IMT, and serum potassium levels; it was negatively associated with body mass Asami, ET AL index (BMI) and family history of CAD (Table IV) . In contrast, PCV was positively associated with hemodialysis vintage, right CA-IMT, and serum potassium and calcium levels; it was negatively associated with BMI, serum ADMA levels, and serum E-selectin levels. In multivariable analyses using the minimum AIC model, the following factors were significantly correlated with higher PAV: age, lower BMI, diabetes mellitus without insulin, and dyslipidemia without statin (Table IV) . In contrast, the following factors were independent predictors of a higher PCV: age, male sex, lower BMI, hemodialysis vintage, diabetes mellitus (with/without insulin therapy), dyslipidemia without statin therapy, and serum IS levels (Table IV) . Indoxyl sulfate as a predictor of an increasing calcium volume: Correlation analysis identified that higher serum IS levels were an independent predictor of a higher PCV [partial regression coefficient (PRC), 2.89; 95% CI, 0.35-5.43; P = 0.03; Figure 1 ]. In contrast, serum IS levels were not significantly correlated with PAV, even after adjustment for confounders, as indicated by univariate analysis (PRC, 0.30; 95% CI, -1.01-1.61; P = 0.66).
Cardiovascular events during the follow-up period:
During the 1 year follow-up period after MDCT, 15 subjects (50.0%) suffered composite cardiovascular events (Supplemental Table II ). Only two subjects died of cardiac causes, including one case of unexplained sudden death and one case of myocardial infarction. The most common cardiovascular event was coronary revascularization (16.7%). Using Kaplan-Meier methodology, the 1 year probability of event-free survival was 50.0% (95% CI: 32.1-67.9%) (Figure 2) .
Discussion
The present study demonstrated that higher serum IS levels are associated with higher PCV but not with higher PAV in patients undergoing hemodialysis, as assessed using 320-row MDCT. Furthermore, the present study showed that age, male sex, lower BMI, hemodialysis vintage, diabetes mellitus (with/without insulin), dyslipidemia without statin, and serum IS levels were associated with higher PCV. These findings are consistent with previous reports of a correlation between CAC deposition and age, 4, 18) hemodialysis vintage, 19) or diabetes mellitus 20, 21) in patients undergoing hemodialysis. Other studies suggested that high BMI is negatively correlated with CAC in patients undergoing hemodialysis. 22, 23) However, only a few studies have provided evidence that CAC is associated with sex, dyslipidemia with/without statin, and serum IS levels in patients undergoing hemodialysis.
It is well known that men rather than women have a higher atheroma burden, more eccentric atheroma, and more diffuse epicardial endothelial dysfunction. 24, 25) These differences are mainly due to the protective effect of estrogen against the formation of coronary plaques in women. 26) A similar protective effect may suppress calcium accumulation in women who are undergoing hemodialysis. Furthermore, low-density lipoprotein cholesterol levels correlate more strongly with CAC than with age, smoking, blood pressure, and fasting insulin. 27) Previous studies have emphasized the role of dyslipidemia in the pathogenesis of CAC in the general population. 28, 29) Furthermore, Tamashiro, et al. reported that a rapid progression of CAC in patients undergoing hemodialysis was associated with higher triglyceride levels and lower highdensity lipoprotein cholesterol levels. 5) In our study, we divided the patients with dyslipidemia into two groups: with statin and without statin. Dyslipidemia without statin was as an independent predictor of both higher PAV and higher PCV. However, dyslipidemia with statin was not significantly correlated with higher PAV or PCV. Recent studies have indicated that high-dose statin therapy leads to a reduction in the necrotic core volume of unstable plaque but to an increase in tissue calcification. 30, 31) No reports have addressed whether this mechanism is applicable to patients undergoing hemodialysis. It may be that because large CAC-like deposits are particularly abundant in ASSOCIATION BETWEEN IS AND CORONARY PLAQUES The parameters that were strongly correlated factors and those missing several values were excluded. The best model was selected using the stepwise approach. * indicated parameters used for multivariable analyses. ACE-I/ARB indicates angiotensin converting enzyme inhibitor/angiotensin II receptor blocker; AIC, Akaike's information criterion; CAD, coronary artery disease; CA-IMT, carotid artery intima-media thickness; CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; and PRC, partial regression coefficient.
patients undergoing hemodialysis, the beneficial effect of statin is limited by the predominance of tissue calcification over necrotic core volume in plaques. Because of the study design, the present study could not assess the duration of statin therapy or the cumulative effect of statin on CAD. However, our data may indicate that patients undergoing hemodialysis diagnosed with dyslipidemia should take statins, even in the presence of extensive CAC deposition because the calcified plaques in the coronary artery are predictors of future adverse coronary event.
6,7)
The association between serum IS levels and PCV identified in the present study contradicts that previously reported, which assessed the association between serum IS levels and CPB or CAC. For example, Taki, et al. showed that traditional cardiovascular risk factors, such as medical history, diabetes mellitus, aging, systolic blood pressure, calcium overload, oxidative stress (lipid peroxides), and advanced glycation end products (pentosidine), but not serum IS levels are associated with extensive CAC in patients undergoing hemodialysis.
12) Their population in- cluded all asymptomatic patients undergoing hemodialysis, whereas our population included only patients undergoing hemodialysis who were suspected of CAD on the basis of certain symptoms or those who had an unstable blood pressure during hemodialysis. Furthermore, they measured CAC using 16-row MDCT, and their calcium threshold was set at > 110 Hounsfield units. In contrast, the present study used a more sensitive and selective method, namely, 320-row MDCT and a calcium threshold of 130 Hounsfield units. In addition, according to basic research, IS contributes to the progression of arterial calcification. 9, 32) Consequently, our findings are more likely to be assured of mechanism for CAC accumulation in patients undergoing hemodialysis. Furthermore, we evaluated independent predictors of high serum IS levels by the same methods used to analyze PCV. Hypertension, longer hemodialysis vintage, and lower LVEF were identified as independent predictors of high serum IS levels (Supplemental Table  III ). Interestingly, there may be an association between serum IS levels and longer hemodialysis vintages. Yamazaki and colleagues showed that serum IS levels were associated with the percentage lipid volume and percentage fibrous volume, as assessed using IB-IVUS and multivariate regression analysis. 11) In the present study, serum IS levels were not significantly associated with PAV. However, because IVUS is invasive, they did not examine the entire coronary artery; furthermore, patients undergoing hemodialysis were excluded from the population. Thus, the present study identified the serum IS levels as a new, clinically meaningful positive marker of PCV but not of PAV.
IS enhanced reactive oxygen species (ROS) production and induced cellular toxicity in endothelial cells. 33, 34) ROS production causes the progression of both atherosclerosis and vascular calcification. An in vitro experiment demonstrated that increased intracellular oxidative stress enhanced osteoblastic differentiation of vascular cells on the basis of the alkaline phosphatase activity and mineralization. 35) Thus, enhanced oxidative stress modulates the differentiation of vascular cells, possibly explaining the enhanced vascular calcification in patients undergoing hemodialysis. Consequently, although the sample size is relatively small, our findings may contribute to understanding the progress mechanism of CAC in patients undergoing hemodialysis. Study limitations: To ensure that the results of the present study are properly interpreted, the number of limitations must be acknowledged. First, the sample size was relatively small, all subjects were drawn from a single center, and the follow-up period was too short to evaluate the long-term effect of the biomarkers. Therefore, the results should be considered preliminary and should only be used to generate hypotheses. In this regard, one indication of the present study was that the effect of IS, a biomarker, is a strong confounding factor. Second, we excluded patients with a history of coronary revascularization, pacemaker implantation, or severe heart failure. Nonetheless, this study suggested a positive association between serum IS levels and CAC load in patients undergoing hemodialysis.
Conclusions:
The present study provided evidence that serum levels of IS, a uremic toxin, are associated with calcium deposition in the coronary arteries of patients undergoing hemodialysis. Thus, serum IS levels might be carefully observed even in patients undergoing hemodialysis. These interesting findings pave the way for future larger trials that aim to elucidate the mechanism of CAC development, which is a major issue in patients undergoing hemodialysis.
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